FOLH1 and neoplasm: Therefore, PERCIST was not considered sufficient to distinguish good responders from poor responders to 223Ra treatment, and the authors decided to assess novel parameters of 68Ga-PSMA PET/CT as total tumor volume and voxel-wise heterogeneity.